An open-label, randomized, parallel-group, multicenter, non-inferiority trial comparing the effectiveness and safety of an immuno-guided strategy versus a viremia-guided strategy for the prevention of cytomegalovirus infection in seropositive kidney transplant recipients.
Phase of Trial: Phase IV
Latest Information Update: 17 Apr 2017
Price : $35 *
At a glance
- Drugs Valganciclovir (Primary) ; Ganciclovir
- Indications Cytomegalovirus infections
- Focus Therapeutic Use
- 14 Apr 2017 Status changed from recruiting to discontinued.
- 14 Sep 2013 New trial record